AU2003245903B2 - The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases - Google Patents

The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases Download PDF

Info

Publication number
AU2003245903B2
AU2003245903B2 AU2003245903A AU2003245903A AU2003245903B2 AU 2003245903 B2 AU2003245903 B2 AU 2003245903B2 AU 2003245903 A AU2003245903 A AU 2003245903A AU 2003245903 A AU2003245903 A AU 2003245903A AU 2003245903 B2 AU2003245903 B2 AU 2003245903B2
Authority
AU
Australia
Prior art keywords
inhibitor
hyperlipidemia
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003245903A
Other languages
English (en)
Other versions
AU2003245903A1 (en
Inventor
David Grenville Holmes
Thomas Edward Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003245903A1 publication Critical patent/AU2003245903A1/en
Application granted granted Critical
Priority to AU2006246483A priority Critical patent/AU2006246483B9/en
Publication of AU2003245903B2 publication Critical patent/AU2003245903B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003245903A 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases Ceased AU2003245903B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006246483A AU2006246483B9 (en) 2002-06-03 2006-11-30 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03
US60/385,220 2002-06-03
PCT/EP2003/005762 WO2003101448A1 (en) 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006246483A Division AU2006246483B9 (en) 2002-06-03 2006-11-30 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Publications (2)

Publication Number Publication Date
AU2003245903A1 AU2003245903A1 (en) 2003-12-19
AU2003245903B2 true AU2003245903B2 (en) 2006-11-30

Family

ID=29712145

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003245903A Ceased AU2003245903B2 (en) 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
AU2006246483A Ceased AU2006246483B9 (en) 2002-06-03 2006-11-30 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006246483A Ceased AU2006246483B9 (en) 2002-06-03 2006-11-30 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Country Status (25)

Country Link
US (2) US20050176806A1 (enExample)
EP (1) EP1513519B1 (enExample)
JP (2) JP2005532338A (enExample)
KR (1) KR20050012771A (enExample)
CN (2) CN100402026C (enExample)
AT (1) ATE422884T1 (enExample)
AU (2) AU2003245903B2 (enExample)
BR (1) BR0311535A (enExample)
CA (1) CA2487297C (enExample)
CY (1) CY1112800T1 (enExample)
DE (1) DE60326232D1 (enExample)
DK (1) DK1513519T3 (enExample)
EC (1) ECSP045469A (enExample)
ES (1) ES2321600T3 (enExample)
IL (1) IL165181A (enExample)
MX (1) MXPA04012149A (enExample)
NO (1) NO333585B1 (enExample)
NZ (1) NZ536832A (enExample)
PL (1) PL210408B1 (enExample)
PT (1) PT1513519E (enExample)
RU (1) RU2362555C2 (enExample)
SG (1) SG154333A1 (enExample)
SI (1) SI1513519T1 (enExample)
WO (1) WO2003101448A1 (enExample)
ZA (1) ZA200409136B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532338A (ja) * 2002-06-03 2005-10-27 ノバルティス アクチエンゲゼルシャフト 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
ES2684325T5 (es) * 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN113811359A (zh) * 2019-03-22 2021-12-17 拉什大学医学中心 用于溶酶体贮积症的经鼻基因递送和口服肉桂酸、油酰胺或吉非贝齐的组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
TW222626B (enExample) * 1991-07-22 1994-04-21 Pfizer
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
ES2487897T3 (es) * 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
CA2464995A1 (en) * 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP2005532338A (ja) * 2002-06-03 2005-10-27 ノバルティス アクチエンゲゼルシャフト 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
KR101368525B1 (ko) * 2005-09-20 2014-03-06 노파르티스 아게 저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
US6166063A (en) * 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

Also Published As

Publication number Publication date
AU2006246483A1 (en) 2006-12-21
PL374016A1 (en) 2005-09-19
CN101273987A (zh) 2008-10-01
ECSP045469A (es) 2005-01-28
NZ536832A (en) 2006-11-30
IL165181A (en) 2010-06-16
JP2005532338A (ja) 2005-10-27
IL165181A0 (en) 2005-12-18
NO20045452L (no) 2005-03-01
EP1513519B1 (en) 2009-02-18
ATE422884T1 (de) 2009-03-15
HK1074794A1 (en) 2005-11-25
AU2006246483B2 (en) 2010-06-24
PL210408B1 (pl) 2012-01-31
CN1658867A (zh) 2005-08-24
AU2006246483B9 (en) 2010-08-12
CY1112800T1 (el) 2016-02-10
DK1513519T3 (da) 2009-06-02
ES2321600T3 (es) 2009-06-09
CN100402026C (zh) 2008-07-16
MXPA04012149A (es) 2005-04-19
AU2003245903A1 (en) 2003-12-19
RU2004139029A (ru) 2005-08-27
SI1513519T1 (sl) 2009-06-30
NO333585B1 (no) 2013-07-15
US20120014907A1 (en) 2012-01-19
SG154333A1 (en) 2009-08-28
DE60326232D1 (de) 2009-04-02
CA2487297A1 (en) 2003-12-11
US20050176806A1 (en) 2005-08-11
CA2487297C (en) 2011-08-09
RU2362555C2 (ru) 2009-07-27
JP2010155866A (ja) 2010-07-15
ZA200409136B (en) 2005-07-27
BR0311535A (pt) 2005-02-22
PT1513519E (pt) 2009-05-06
KR20050012771A (ko) 2005-02-02
WO2003101448A1 (en) 2003-12-11
EP1513519A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
AU2003245903B2 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
EP1741447B1 (en) Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
IL185384A (en) Pharmacological compositions for lowering plasma lipoprotein (A) levels and lowering risk factors for cardiovascular disease
EP3071198A1 (en) Treatment of homozygous familial hypercholesterolemia
JP2005532338A5 (enExample)
Basak et al. An overview on management of diabetic dyslipidemia
WO1998001119A2 (en) Pharmaceutical compositions comprising simvastatin
TWI302457B (en) A pharmaceutical composition for improving blood lipid or reducing blood homocysteine
SK11112001A3 (sk) Použitie prostriedku znižujúceho cholesterol
NZ548902A (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
HK1074794B (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
HUP0201597A2 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
Marks Control of lipid disorders in patients with atherosclerotic vascular disease
HK1085377B (en) Combination of a dpp-iv inhibitor and a ppar-alpha compound
HK1102422B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1085377A1 (en) Combination of a dpp-iv inhibitor and a ppar-alpha compound
HK1102405B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired